Anesthesiology

Graphium Health Acquires The ABG Anesthesia Data Group Strengthening Anesthesia Quality and Safety Initiatives

Retrieved on: 
Thursday, January 11, 2024
Anesthesiology, Quality, Hospital, Data management, Anesthesia, Joint Commission, MIPS, Joint, Acquisition, Safety, CMS, ABG, Patient safety, QI, Service provider, Health, Nursing

DRAPER, Utah, Jan. 11, 2024 /PRNewswire/ -- Graphium Health, a leader in anesthesia healthcare technology solutions, proudly announces the acquisition of The ABG Anesthesia Data Group, LLC (ABG), a pivotal move aimed at bolstering advancements in anesthesia quality and safety.

Key Points: 
  • DRAPER, Utah, Jan. 11, 2024 /PRNewswire/ -- Graphium Health, a leader in anesthesia healthcare technology solutions, proudly announces the acquisition of The ABG Anesthesia Data Group, LLC (ABG), a pivotal move aimed at bolstering advancements in anesthesia quality and safety.
  • ABG has been at the forefront of QCDR management and has pioneered initiatives that have fostered quality and safety programs within anesthesia practices.
  • Current ABG clients will submit 2023 performance year data without changes and Graphium Health will provide additional support to the ABG team.
  • The acquisition underscores Graphium Health's vision to advance anesthesia quality and safety initiatives, empowering hospital administrators and providers with innovative tools to navigate evolving regulatory landscapes effectively.

Emergency medicine residencies more likely to go unfilled at for-profit and newly accredited programs

Retrieved on: 
Monday, January 8, 2024
Interview, Emergency medicine, Envision, Student, Bankruptcy, Hospital, Solution, Violence, Association, Anesthesiology, American College, Burnout, Review, Patient, Organization, Female, Bed, Emergency, Nursing

The number of unfilled positions in emergency medicine residency programs surged in 2022 and 2023, with the trend most pronounced at programs that were recently accredited or under for-profit ownership.

Key Points: 
  • The number of unfilled positions in emergency medicine residency programs surged in 2022 and 2023, with the trend most pronounced at programs that were recently accredited or under for-profit ownership.
  • The proportion of medical students applying for emergency medicine residencies dropped by 16.8% from 2021 to 2022 and declined another 18.1% from 2022 to 2023.
  • Deepening the problem is the fact that the number of emergency medicine residency programs has grown at the same time.

No checks on the for-profit sector

  • Currently, there are no limits on the number of residency programs or positions in emergency medicine.
  • Despite the fact that positions are already going unfilled, eight new emergency medicine residency programs were accredited during the 2022-23 academic year.

More positions, lower demand

  • In our recent paper, my team and I calculated the number of emergency medicine residency programs that filled all positions in the past two match cycles.
  • Our study shows that in 2022, 277 emergency medicine residency programs offered 2,921 positions and had 219 unfilled positions.
  • Third, emergency medicine residency programs with for-profit clinical sites were less likely to fill all residency positions.

Possible solutions

  • In 1996, the anesthesiology specialty saw the proportion of filled residency positions drop to 45%, an all-time low.
  • No research yet has evaluated board exam pass rates of emergency medicine residents graduating from newly accredited or for-profit clinic sites.
  • And more female residents would be drawn into emergency medicine if disparities in pay and concerns over violence in emergency rooms were systematically resolved.


Cameron Gettel receives funding from the National Institute on Aging (NIA) of the National Institutes of Health and the American Board of Emergency Medicine / National Academy of Medicine Fellowship. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation or approval of the manuscript.

Envision Healthcare Renews In-Network Agreement With Blue Cross and Blue Shield of Texas

Retrieved on: 
Thursday, January 4, 2024
Professional Services, Health, Insurance, Practice Management, Health Insurance, Managed Care, Radiology, Blue Shield, Trauma, Health care, Blue Cross, Physician, Emergency medicine, Hospital medicine, Neonatology, Medicare, Patient, Envision Healthcare, Anesthesiology, Interim, Medicaid, Nursing care plan, Hospital

Envision Healthcare, a leading national medical group, has executed a multiyear, statewide agreement with Blue Cross and Blue Shield of Texas (BCBSTX), the state’s largest customer-owned health insurer, to provide its commercial, Managed Medicare and Managed Medicaid members in Texas with in-network care provided by Envision clinicians.

Key Points: 
  • Envision Healthcare, a leading national medical group, has executed a multiyear, statewide agreement with Blue Cross and Blue Shield of Texas (BCBSTX), the state’s largest customer-owned health insurer, to provide its commercial, Managed Medicare and Managed Medicaid members in Texas with in-network care provided by Envision clinicians.
  • The renewed agreement provides millions of BCBSTX members in Texas with in-network access to Envision physicians and advanced practice providers specializing in anesthesiology, emergency medicine, hospital medicine, neonatology, radiology, trauma and critical care.
  • “Our skilled and dedicated team of clinicians continue to innovate and advance the delivery of high-quality, patient-centered care,” said Henry Howe, Interim Chief Executive Officer of Envision Healthcare.
  • “We are pleased to build on our relationship with BCBSTX to address the evolving needs of the Texas community as it continues growing.

NORTHSTAR ANESTHESIA TO PROVIDE ANESTHESIOLOGY SERVICES FOR PORTNEUF HEALTH

Retrieved on: 
Wednesday, January 3, 2024
Culture, Partnership, Ardent Health Services, Rocky Mountains, Anesthesia, Health care, Anesthesiology, Patient, NorthStar, Development, Hospital

IRVING, Texas, Jan. 3, 2024 /PRNewswire/ -- NorthStar Anesthesia, an industry leader in anesthesia care, has expanded its high-quality anesthesia services to Portneuf Health in Pocatello, Idaho.

Key Points: 
  • IRVING, Texas, Jan. 3, 2024 /PRNewswire/ -- NorthStar Anesthesia, an industry leader in anesthesia care, has expanded its high-quality anesthesia services to Portneuf Health in Pocatello, Idaho.
  • Portneuf turned to NorthStar Anesthesia to support the modernization and scale of its anesthesia services to accommodate growing case volumes and better serve the Pocatello community and region.
  • "Our partnership with NorthStar Anesthesia will help us to better serve our community and the region, with quality resources and first-class reputation for high-quality patient care," said Jordan Herget, President and CEO of Portneuf Health.
  • "We are excited for NorthStar's first venture into Idaho and look forward to working with the team at Portneuf, as well as expanding our collaboration with their parent company Ardent Health Services," said NorthStar Anesthesia CEO Adam Spiegel.

Milestone Announces Agreement with Bioline Supply to Distribute the CompuFlo® Epidural System and Related Disposables Across Spain

Retrieved on: 
Tuesday, November 28, 2023
Pain management, Risk, Physician, Pain, Injection, Bioline, Hospital, Spine, Anesthesiology, Patient, Safety, MLSS

ROSELAND, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced it has entered into an agreement with Bioline Supply to distribute the CompuFlo® Epidural System and related disposables in Spain.

Key Points: 
  • ROSELAND, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced it has entered into an agreement with Bioline Supply to distribute the CompuFlo® Epidural System and related disposables in Spain.
  • Bioline is a premier distributor of medical devices and equipment, supporting many hospitals and pain clinics across Spain.
  • In connection with the agreement, Milestone Scientific has commenced sales and shipments of its CompuFlo Epidural Instrument and consumables to Spain.
  • Giacomo Damiani, CEO of Bioline Supply, stated, “We are pleased to add the CompuFlo® Epidural System to our product portfolio.

Texas Spine Consultants Partners with United Musculoskeletal Partners

Retrieved on: 
Wednesday, December 27, 2023
General Health, Health, Surgery, Practice Management, TSC, Patient, UMP, Partnership, Spine, Anesthesiology

United Musculoskeletal Partners (UMP), a leader in musculoskeletal care delivery, is pleased to announce a partnership with Texas Spine Consultants (TSC), a Dallas-based provider group specializing in spine surgical management.

Key Points: 
  • United Musculoskeletal Partners (UMP), a leader in musculoskeletal care delivery, is pleased to announce a partnership with Texas Spine Consultants (TSC), a Dallas-based provider group specializing in spine surgical management.
  • Founded in 2008, the TSC practice includes four spine surgeons, one anesthesiology and pain medicine physician, and four advanced practice providers.
  • TSC provides comprehensive spine care serving patients in North Texas with locations in Addison and Plano.
  • We are pleased to welcome them to the UMP team in Texas,” said Brian Cormican, CEO – UMP Texas.

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

Retrieved on: 
Wednesday, December 27, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Diabetic neuropathy, LID, Pregabalin, Depression, Pain, Pain management, Gold, MD, Doctor of Philosophy, Chung, Gabapentin, Nerve, Patent, University, Anxiety, Neuropathic pain, CNS, Anesthesiology, Hyperalgesia, European Patent Convention, NMDAR, Central nervous system, Allodynia, EPO, Journal, Pharmacology, Levodopa-induced dyskinesia, Pharmaceutical industry

The patent, once granted, will not expire until at least 2034 and will become part of Vistagen’s global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.

Key Points: 
  • The patent, once granted, will not expire until at least 2034 and will become part of Vistagen’s global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.
  • In the study, AV-101 prodrug was systematically administered in four rat models of pain to examine its analgesic and behavioral profile.
  • The preclinical study was conducted by Tony L. Yaksh, PhD, Professor of Anesthesiology and Pharmacology at the University of California, San Diego.
  • Vistagen plans to seek potential strategic collaborations to further advance the clinical development and commercialization of AV-101.

Trevena Reports Third Quarter 2023 Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
CNS, Sale, Webcast, TMS, POC, Senior, University, Pain, Plasma, Rheumatology, Cleveland Clinic, Patient, Transcranial magnetic stimulation, Psychiatry, Trevena, ARTEMIS, NIH, Epilepsy, Abstract, EEG, S1P, ASA, Central nervous system, Chronic pain, Alertness, Neuropathic pain, Pharmaceutical industry, Medicine, Anesthesiology

ET

Key Points: 
  • ET
    CHESTERBROOK, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended September 30, 2023 and provided an overview of its recent operational highlights.
  • “There is a significant need for safe and effective non-opioid therapies in pain, and for novel mechanisms for the treatment of epilepsy.
  • The Company previously announced preliminary topline data from two Phase 1 proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement.
  • As part of the R-Bridge Financing, Trevena may receive an additional $10 million upon achievement of either a commercial or financing milestone.

Biospectal OptiBP Receives First-Ever CE Mark for a Smartphone Blood Pressure Monitoring App

Retrieved on: 
Wednesday, December 6, 2023
Apps, Applications, Mobile, Wireless, Technology, Medical Devices, Software, Audio, Video, Other Health, General Health, Health, Data Management, World Health Organization, Hypertension, Research, Android, Electronics, MDR, Smartphone, Patient, European, Algorithm, CE, Google Play, Anesthesiology, System, Lausanne University Hospital, Partnership, CHUV, Certification, Telehealth, Professor, Blood pressure, Medical device, Pharmaceutical industry, Microtechnology

Biospectal , the remote monitoring and biosensing software company, today announced it has received European CE MDR Class IIa medical device certification for its optical fingertip blood pressure monitoring app, OptiBP™ — the first and only software app worldwide to receive the CE mark for measuring blood pressure on a smartphone.

Key Points: 
  • Biospectal , the remote monitoring and biosensing software company, today announced it has received European CE MDR Class IIa medical device certification for its optical fingertip blood pressure monitoring app, OptiBP™ — the first and only software app worldwide to receive the CE mark for measuring blood pressure on a smartphone.
  • The Biospectal OptiBP app uses the built-in camera lens on a smartphone to record an individual’s blood flow easily via their fingertip.
  • OptiBP records fingertip blood flow optically and transforms that information into a pulse wave that it analyzes to estimate blood pressure.
  • By allowing blood pressure to be measured at the ‘point of patient,’ OptiBP enables more frequent, trackable and shareable information to support better blood pressure management and better life outcomes.

U.S. Anesthesia Partners Files Motion to Dismiss FTC’s Misguided Civil Complaint

Retrieved on: 
Tuesday, November 21, 2023
Professional Services, Medical Supplies, Health, Surgery, Legal, Other Health, General Health, Complaint, USAP, Protocol, Patient, Anesthesia, Federal Trade Commission, District court, FTC, Anesthesiology

U.S. Anesthesia Partners (“USAP”), a leading provider of high-quality anesthesia care, today filed a motion to dismiss the Federal Trade Commission’s (FTC) civil complaint alleging that certain USAP business practices violate U.S. competition laws.

Key Points: 
  • U.S. Anesthesia Partners (“USAP”), a leading provider of high-quality anesthesia care, today filed a motion to dismiss the Federal Trade Commission’s (FTC) civil complaint alleging that certain USAP business practices violate U.S. competition laws.
  • USAP filed a motion to dismiss the complaint because, among other things, the FTC has inaccurately represented the anesthesia market in Texas and has failed to properly allege that USAP has monopoly power by charging more than a competitive price.
  • It is an attack on our independent, physician-owned and physician-led medical practice rather than a valid complaint that has credible allegations of anticompetitive harm.
  • Dr. Derek Schoppa, another practicing USAP physician in Texas and a USAP Board member, added: “The FTC’s allegations are misguided.